Headache News and Research

Latest Headache News and Research

Pregnant women and extremely obese people at high risk of flu complications

Pregnant women and the extremely obese are among those at high risk for complications from the flu - including death - and should be tested and begin antiviral treatment promptly if they are sick enough to be hospitalized with flu symptoms, according to updated guidelines released by the Infectious Diseases Society of America.

19 Dec 2018

Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel's Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii from serum and plasma specimens.

19 Dec 2018

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in Brazil to Eurofarma Laboratorios S.A. Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.

17 Dec 2018

Study compares pain-related diagnoses in First Nations and non-First Nations children, youth

First Nations children and youth are experiencing more pain than non-First Nations children, but do not access specialist or mental health services at the same rate as their non-First Nations peers, found new research published in CMAJ.

10 Dec 2018

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

Nasal surgery can reduce or eliminate chronic headaches in selected patients

Nasal surgery to relieve obstructed breathing can reduce or eliminate chronic headaches in selected patients, reports a paper in the December issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons.

29 Nov 2018

FDA approves new drug for treatment of rare autoimmune disorder

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

29 Nov 2018

Researchers harness visible light to develop safer building block for drug discovery

When you reach for a bottle of acetaminophen, you may be looking for relief from a headache. But if you take more than what is recommended, the drug can damage your liver.

22 Nov 2018

FDA approves antibacterial drug to treat travelers' diarrhea

The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

17 Nov 2018

John Snow Labs launches new Data Market to help healthcare and life science innovators

John Snow Labs, an award-winning global data operations and AI company, today announces the launch of John Snow Labs Data Market. The Data Market is an online store that allows users to subscribe to datasets and/or data packages in the healthcare and life science domain.

13 Nov 2018

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

Mosquitoes of the genus Anopheles are well known as primary vectors of malaria. But a new study suggests that Anopheles species, including some found in the United States, also are capable of carrying and transmitting an emerging pathogen, Mayaro virus, which has caused outbreaks of disease in South America and the Caribbean.

9 Nov 2018

House Dems in new seats of power will steer health policy, attack drug prices

For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans' tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed.

7 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Stroke specialists often see conditions known as stroke "mimics" and "chameleons" that can complicate accurate diagnoses, Loyola Medicine neurologists report in the November 2018 issue of Neuroimaging Clinics of North America.

26 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Headache News and Research

Latest Headache News and Research

Pregnant women and extremely obese people at high risk of flu complications

Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Study compares pain-related diagnoses in First Nations and non-First Nations children, youth

New strategies may improve performance of CAR-T cell therapy in treating cancer

Nasal surgery can reduce or eliminate chronic headaches in selected patients

FDA approves new drug for treatment of rare autoimmune disorder

Researchers harness visible light to develop safer building block for drug discovery

FDA approves antibacterial drug to treat travelers' diarrhea

John Snow Labs launches new Data Market to help healthcare and life science innovators

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

House Dems in new seats of power will steer health policy, attack drug prices

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in